Immuneering (IMRX) Operating Income: 2020-2023
Historic Operating Income for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$16.3 million.
- Immuneering's Operating Income fell 16.57% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 12.89%. This contributed to the annual value of -$58.4 million for FY2023, which is 12.89% down from last year.
- As of Q4 2023, Immuneering's Operating Income stood at -$16.3 million, which was down 17.06% from -$13.9 million recorded in Q3 2023.
- Immuneering's Operating Income's 5-year high stood at -$3.2 million during Q2 2020, with a 5-year trough of -$16.3 million in Q4 2023.
- Moreover, its 3-year median value for Operating Income was -$13.1 million (2022), whereas its average is -$12.0 million.
- Data for Immuneering's Operating Income shows a maximum YoY crashed of 146.69% (in 2021) over the last 5 years.
- Immuneering's Operating Income (Quarterly) stood at -$5.8 million in 2020, then plummeted by 90.45% to -$11.1 million in 2021, then fell by 25.81% to -$14.0 million in 2022, then decreased by 16.57% to -$16.3 million in 2023.
- Its Operating Income was -$16.3 million in Q4 2023, compared to -$13.9 million in Q3 2023 and -$13.5 million in Q2 2023.